N. Ringdal et al., ONSET AND DURATION OF ACTION OF SINGLE DOSES OF FORMOTEROL INHALED VIA TURBUHALER(R), Respiratory medicine, 92(8), 1998, pp. 1017-1021
Citations number
19
Categorie Soggetti
Respiratory System","Cardiac & Cardiovascular System
The aim of the study was to investigate the time of onset and the dura
tion of the bronchodilating effect of different doses of formoterol ad
ministered via Tulbuhaler(R) in patients with moderate asthma. Thirty-
one patients (five women) with a mean forced expiratory volume in s (F
EV1) of 1.97 +/- 0.541 and a mean reversibility of 31 +/- 14% of basel
ine were included in this double-blind. randomized. placebo-controlled
and cross-over study. The patients inhaled single doses of placebo, i
.e. 6, 12, 24, or 48 mu g formoterol fumarate, on 5 separate days. Ser
ial measurements of specific airways conductance (SGaw) and FEV1 were
performed at regular time intervals for 12 h. The majority of the pati
ents had at least a 50% increase in SGAW within 1-4 min after administ
ration of all active treatments. The maximum increase in FEV1 over pla
cebo was dose-dependent: 12% (6 mu g), 18% (12 mu g), 19% (24 mu g), a
nd 26% (48 mu g) (P<0.001). Twelve hours after administration of 6. 12
, 24, and 48 mu g formoterol, the mean increase in FEV1 was still 7%,
15%, 18% and 27%, respectively, above the value following placebo. Hea
dache was the most frequently reported adverse event in all treatments
including placebo. After inhalation of 48 mu g, three patients experi
enced mild tremor lasting for less than 1 h; likewise, one patient exp
erienced the same event for 3 h after placebo. Formoterol administered
via Turbuhaler(R) gave a rapid and dose-related bronchodilating effec
t lasting for 12 h and was well tolerated.